Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chiara Mercinelli
Observed names:
C. MERCINELLI,
C. Mercinelli,
CHIARA MERCINELLI,
Chiara MERCINELLI
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
University of Pisa,
University of Wisconsin–Madison,
Vita-Salute San Raffaele University,
University Medical Center Freiburg,
IRCCS Ospedale San Raffaele,
Azienda Ospedaliera Universitaria Pisana,
IRCCS San Raffaele Roma
show all 7
ORCID:
0000-0003-1165-1776
Observed ORCID:
0000-0003-1165-1776
OpenAlex ID:
A5085186522
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024
·
Brigida Anna Maiorano
, Massimo Di Maio
, et al.
·
JAMA Network Open
·
66
Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
2023
·
Simone Ferretti
, Chiara Mercinelli
, et al.
·
Research and Reports in Urology
·
55
PDF
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
2024
·
Giorgio Brembilla
, Giuseppe Basile
, et al.
·
Radiology
·
36
PDF
Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer
2023
·
Andrea Necchi
, Giuseppe Basile
, et al.
·
British Journal of Urology
·
29
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review
2024
·
Emanuele Crupi
, Tiago Costa de Padua
, et al.
·
JCO Precision Oncology
·
26
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
2022
·
Marzia Del Re
, Stefania Crucitta
, et al.
·
Journal of Translational Medicine
·
26
PDF
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer
2024
·
Chiara Mercinelli
, Marco Moschini
, et al.
·
Journal of Clinical Oncology
·
25
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
2026
·
Andrea Necchi
, Brigida A Maiorano
, et al.
·
The Lancet Oncology
·
23
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
2024
·
Roger Li
, Luigi Nocera
, et al.
·
European Urology Oncology
·
22
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
2025
·
Pietro Scilipoti
, Paolo Zaurito
, et al.
·
European Urology
·
20
T-cell Engagers in Prostate Cancer
2025
·
Chadi Hage Chehade
, Zeynep Irem Ozay
, et al.
·
European Urology
·
20
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer
2026
·
Valentina Tateo
, Giuseppe Basile
, et al.
·
European Urology
·
16
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
2020
·
Stefania Crucitta
, Marzia Del Re
, et al.
·
Cancer Chemotherapy and Pharmacology
·
14
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)
2024
·
Elisabetta Gambale
, Marco Maruzzo
, et al.
·
Clinical Genitourinary Cancer
·
12
PDF
First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).
2025
·
Andrea Necchi
, Joep de Jong
, et al.
·
Journal of Clinical Oncology
·
11
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
2024
·
Antonio Cigliola
, Marco Moschini
, et al.
·
Journal of Clinical Oncology
·
11
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study
2024
·
Antonio Cigliola
, Alina Basnet
, et al.
·
JCO Precision Oncology
·
10
Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
2025
·
Brigida Anna Maiorano
, Chiara Mercinelli
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
9
Immune-based Therapies for Penile Cancer
2024
·
Majd Al Assaad
, Houssein Safa
, et al.
·
Urologic Clinics of North America
·
9
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives
2025
·
Antonio Cigliola
, Brigida Anna Maiorano
, et al.
·
Cancers
·
8
PDF
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
2025
·
Brigida Anna Maiorano
, Martina Catalano
, et al.
·
European Urology Open Science
·
8
The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies
2024
·
Rachel Daher
, Andrew Ruplin
, et al.
·
Critical Reviews in Oncology/Hematology
·
8
First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).
2025
·
Brigida Anna Maiorano
, Joep de Jong
, et al.
·
Journal of Clinical Oncology
·
7
Insights into the management of penile squamous cell carcinoma: from conventional approaches to emerging novel therapies
2024
·
Houssein Safa
, Chiara Mercinelli
, et al.
·
Expert Opinion on Pharmacotherapy
·
7
LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial
2025
·
A. Necchi
, C. Mercinelli
, et al.
·
Annals of Oncology
·
6
PDF
Show more works
View as search
Works count:
182
Citation count:
589
H-index:
13
I10-index:
17
Year
Topic
Type